Effective decision-making hinges on a thorough analysis, encompassing all available data, in order to form a well-informed judgment. It is imperative to consider both sides of any proposition, warts and all. Yet, in the realm of structured products, the occasional incidence of negative press often overshadowed their performance, potentially due to the ease of discrediting them rather than investing the time to construct a comprehensive understanding of these investment options, which can prove beneficial to a client's portfolio.
It is essential to embrace the prevailing negative perceptions surrounding structured products to comprehend why they are sometimes disregarded as viable choices for clients. Consequently, in the coming weeks, the team at StructuredProductReview.com will consider the case against structured products and present a defence.
Throughout this series of articles, we will examine some of the old arguments that have occasionally been used to dismiss an entire sector of investments. These include:
Precipice bonds
'High charge'
Keydata
Lehman Brothers / counterparty risk
'Loss of dividends'
Complexity
Capped returns
It goes without saying that we believe there is a robust defence against these matters, some of which are more than twenty years old but if you are a critic of structured products or know of other arguments against them, we eagerly invite your input. Please share your insights and suggestions by emailing enquiry@StructuredProductReview.com.
Conversely, if you champion structured products and wish to contribute your perspective on the aforementioned matters, or any additional issues deserving attention, we encourage you to step forward and share your insights.
Also in this section
- A share of spread bets on steroids?
- Product focus - September 2024
- Maturities of the month - August 2024
- Right on time
- Product focus - August 2024
- Keep calm and zoom out
- 2,000 and counting
- Q2 2024 maturity results
- 20 years of autocall maturities
- Product focus - June 2024
- Fixed income or interest?
- Maturities of the month - May 2024
- The barrier debate - revisited
- Product focus - April 2024
- Maturities of the month - April 2024
- Time to call
- I don't believe markets are ever too high for Structured products!
- Notes on counterparty exposure
- Return of Nikkei
- Q1 2024 issuance
- Q1 2024 maturity results
- Structured Products – AAAAAGH!
- Hop in CIBC
- Re-enter Santander
- How to build a financial fortune - revisited
- Issuance in 2023
- Where's the risk?
- Questionable offerings
- Challenging the case against structured products - 'Loss of dividends'
- Navigating the investment landscape
- Challenging the case against structured products - Counterparty risk
- 6-year autocalls approaching final destination
- 1,750 FTSE capital at risk autocall maturities
- The leopard that changed her spots
- Q3 2023
- Challenging the case against structured products - Keydata
- Dilemmas for UK IFA's and the unique role of Structured Products
- 'High charges'
- Precipice bonds
- Intro
- FTSE 100 Contingent Income
- Indexing the indices
- Something different
- Investing through volatility
- 100 10:10s
- The best or worst?
- The 10%/25% 'Rule' that never was
- Structured products and the yield curve
- Fixed income: Capital at risk?
- Prospects for UK inflation - and fun with A.I!
- The Barrier Debate
- More Deposits for now
- Last of the Americans
- What if?
- Time heals all wounds, we hope...
- How to diversify portfolios using structured products?
- The Proof Is In The Pudding...
- Debunking Structured Misconceptions
- 1,500 FTSE Capital-at-Risk Autocall Maturities
- Q3 2022 Maturity Results
- What do we prefer?
- Deposits vs Capital ‘Protected’
- There’s time yet…
- Where did you invest your clients?
- A Six-Month Reflection
- Return of the Rev Con
- Happy 2nd Birthday FTSE CSDI
- Q2 2022 Maturity Results
- The best and worst yet still the best
- Critique my Suitability - Mariana 10:10 Plan June 2022 (Option 2)
- 10/10 for 55 10:10’s
- Q1 2022 Maturity Results
- 'How to build a financial fortune': a follow up
- Critique my Suitability - Mariana 10:10 Plan April 2022 (Option 2)
- 2021 Capital-at-Risk Autocall Maturity Review
- An unwelcome return...
- CSDI's First Birthday
- Bon Anniversaire
- Introducing the FTSE Custom 100 Synthetic 3.5% Fixed Dividend Index
- Q3 2021 Maturity Results
- Critique my Suitability - Mariana 10:10 Plan October 2021 (Option 2)
- Blurring the lines...
- Beware of false knowledge; it is more dangerous than ignorance
- Good news, bad news...
- Certainty is Certainly a Benefit
- Critique my Suitability - Mariana 10:10 Plan September 2021 (Option 2)
- A Twenty-Year Progression
- Q2 2021 Maturity Results
- Nine 8:8s Post Positive Returns in Falling Markets
- Critique my Suitability
- Q1 2021 Maturity Results
- Morgan Stanley’s Marvelous Maturity Medley
Current Products
We review the UK's retail structured investment sector, providing pertinent support for Professional Advisers and relevant research tools.
View all ⟶